The license allows OGT to commercialize tests developed using the biomarkers and to sublicense the markets to other parties. The biomarkers were developed in the department of Cancer Prevention at the Norwegian Radium Hospital, a part of the Oslo University Hospital. OGT has validated the results from tests showing sensitivity of 93 percent and specificity of 90 percent when using tissue biopsies.
Related Articles on Colon Cancer:
Global Markets Direct Releases Colon Cancer Pipeline Report
Dr. Patricia Raymond Produces Music Video to Raise Colonoscopy Screening Awareness Among African-American Community
Colon Cancer Alliance Praises FDA’s Biosimilars Guidance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
